ARTICLE | Clinical News
Eagle gets CRL for Ryanodex
July 28, 2017 8:24 PM UTC
Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) said FDA issued a complete response letter for Ryanodex dantrolene (EP-4104) to treat exertional heat stroke. FDA has requested an additional clinical trial in the indication, and the company said it is considering its options...
BCIQ Company Profiles
BCIQ Target Profiles